DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tanezumab
Tanezumab
Print PDF Opens in a New Window
Untitled
Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
February 2021 EPS Pipeline Report
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
Targeting Nerve Growth Factor for Pain Management in Osteoarthritis- Clinical Efficacy and Safety
Clinical Protocol a Phase 3 Randomized, Double-Blind
Wednesday, June 12, 2019 4:00Pm
Therapeutic Proteins and Their Use in Posterior Eye Segment Diseases
Roche CEO: Novel Gene Therapies Justify New Payment Models
Ep 3321281 A1
Chronic Pain: an Overview of Mechanisms and Management
A Patient's Guide to Living with Osteoarthritis
Asp6294 Non-Confidential Summary Disclaimer 2
Stembook 2018.Pdf
(CHMP) Agenda for the Meeting on 17-20 May 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
Wo 2016/061562 A2 ©
Top View
WO 2017/176762 Al 12 October 2017 (12.10.2017) P O P C T
(INN) for Biological and Biotechnological Substances
Pipeline Report May 2020
Rxoutlook® 3Rd Quarter 2020
CHMP Agenda of the 20-23 July 2020 Meeting
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Pfizer Reports Second-Quarter 2021 Results
Subcutaneous Tanezumab for Osteoarthritis of the Hip Or Knee
Assessment of the Evolution of Cancer Treatment Therapies
Tanezumab Monoclonal Antibody Against Nerve Growth Factor
Eli Lilly and Company
Pharmaabkommen A1 E
Specialty Pipeline MONTHLY UPDATE
A Systematic Review of the Efficacy and General Safety of Antibodies to NGF
Multiple Mechanisms for Pain - How Can We Improve the Chances of Success?
( 12 ) United States Patent
A View Into Upcoming Specialty & Traditional Drugs
Rxoutlook® 2Nd Quarter 2021
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Update on Pharmacologic Options for Neuropathic Pain
CHMP Agenda of the 25-29 January 2021 Meeting
Com(2010)0397
United States Patent (10) Patent No.: US 9,554,989 B2 Kaplan Et Al
ATC/DDD Classification (Temporary)
PDF of Antibody News
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Efficacy and Safety of Fasinumab in Patients with Chronic Low Back Pain
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Specialty Pipeline MONTHLY UPDATE
Human Medicines Regulations 2012 Advisory Bodies Annual Report 2016
PRAC Agenda 11-14 January 2021
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Annals of the Rheumatic Diseases 2019 6.Pdf
Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
(INN) for Biological and Biotechnological Substances
Tanezumab's Return Shows Pharma Has Held Its Nerve
The Evolution of Nerve Growth Factor Inhibition in Clinical Medicine
Emerging Non-Opioid Drugs for the Management of Chronic Non-Cancer Pain
2021 Virtual Nf Conference June 14 - 16, 2021
NF1 Clinical Pipeline: Active Interventional Drug Therapies
FDA Briefing Document Joint Meeting of Arthritis Advisory Committee And
ELI LILLY and COMPANY 2013 ANNUAL REPORT NOTICE of 2014 ANNUAL MEETING PROXY STATEMENT Determination Leads to Discovery
Us 2019 / 0127401 A1
2017 Integrated Summary Report Lilly Unites Caring with Discovery Lillyto Make Life Better for People for Around the World
U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-In-Class Treatment for Patients with Chronic Pain Due to Moderate-To-Severe Osteoarthritis
CHMP Agenda of the 19-22 July 2021 Meeting
Pfizer Reports Second-Quarter 2019 Results
Non-Opiate Treatments for Chronic Pain
The Development of Treatments for Pain
Antibodies to Watch in 2018